FarmaKology’s Substack

Share this post

FarmaKology Newsletter - Issue #32

www.farmakology.com

FarmaKology Newsletter - Issue #32

FarmaKology
Feb 14, 2020
Share this post

FarmaKology Newsletter - Issue #32

www.farmakology.com

Pacific United, LLC

Dr. Nice Moisturizing Gel

“helping mothers continue to breastfeed successfully”

Dr. Nice Moisturing Gel, a patent-protected product, has been seven years in R&D while being sold and manufactured the past three years as we continue to expand our market territories.

website is: www.nicebreastfeeding.com

Company Overview

Opportunity

Breastfeeding

Worldwide, over 130 million babies are born every year. Approximately 50 percent of mothers initiate breastfeeding within one hour of birth and continue for at least two years.

The global breastfeeding industry has been on an upward growth cycle since the year 2000, with market size valued at $1.41 billion USD in 2018 and is expected to reach $2.55 billion USD by 2026, expanding at a compound annual growth rate (CAGR) of 7.8%, according to Grand View Research (GVR) reports.

Learn more from here.

Dr. Nice Moisturizing Gel

Dr. Nice Moisturizing Gel® was developed by Dr. Frank J. Nice, RPh, DPA, CPHP to help nursing mothers continue to breastfeed successfully. It is made of 100% natural components with an advanced biocompatible hydrogel formulation that provides a unique, instant cooling relief for abraded and painful nipples.

The gel forms a skin-like protective layer that is breathable and serves as a shield on the breast area, allowing the skin to heal and strengthen on its own.

Dr. Nice Moisturizing Gel’s pending patent and issued trademark are protected in 185 countries and territories. It is registered with the FDA and the State Department.

Learn more from here.

United States and World Market

In the United States, approximately four (4) million babies are born each year with over 83% of new mothers breastfeeding and 91 percent purchasing some type of topical product to help alleviate pain and heal abrasions caused by breastfeeding.

This represents an opportunity to gain a market share of three (3) million new customers in the United States alone each year for Dr. Nice Moisturizing Gel.

Learn more from here.

The Competition

1. Lansinoh (lanolin) has a 65 percent market share of the breastfeeding industry. Hospitals are looking to move away rapidly from the use of lanolin based products as they have shown to be messy, need to be wiped off before breastfeeding, potentially toxic, prone to allergic reactions, ineffective, occlusive, bacterial and fungal prone, and provide no analgesia, in addition to a general overall dislike by the breastfeeding community.

2. Medihoney is a highly purified honey product that has shown promise as a soothing and healing agent but does not possess any analgesic and antibacterial and antifungal properties and is not as breathable for the skin as peppermint oil gel. It does offer the opportunity to be used in addition to peppermint oil gel for possible additive properties.

3. Coconut oil, Shea butter, and similar products are very similar is application and use as Medihoney and could be used in addition to peppermint oil gel.

4. Mothers’ own expressed breast milk is used often, as it is readily available and has better antibacterial and antifungal properties and soothing and healing qualities at higher rates than any product on the market except for peppermint oil gel. It can certainly be used along with the peppermint oil gel with no need to wash off before breastfeeding.

Learn more from here.

Outlook

Based on the statistics, we expect our product to gain 35 to 40 percent of the lanolin market share within the next two (2) years.

Many of our hospital customers, such as LifeBridge Health and Sinai, have ordered Dr. Nice Moisturizing Gel supply on par with their current supply of lanolin. We expect in the next two years that other hospital systems will follow suit. That represents 65 percent of market share, or 1.95 million new mothers guaranteed to be introduced to Dr. Nice Moisturizing Gel every year.

Learn more from here.

Target Markets

1. Hospitals currently providing lanolin-based products to their mothers, including Baby- friendly children’s hospitals. We have developed a single-use pack, a 3 mL trial size bottle, and a 15 mL bottle. The trial size bottle is the most cost-effective option for hospitals.

2. Lactation Consultants who act as sales representatives and potential distributors for the 15 mL full-size bottle.

3. Pharmacies “should” stock and sell the 15 mL full-size bottle. Current Point of Sale (POS) displays and marketing materials have already been generated.

4. International licensed distributors will be certified based on country and/or territory.This will mitigate the logistical nightmare of multiple export chains and allow the individual foreign distributors to sub-distribute, as they desire.

5. Women, Infants, and Children (WIC) programs at state levels provide cost-effective single packs to low income clients. Currently, we are working with the WIC programs in Georgia, Iowa, Kansas, Maryland, New Jersey, North Carolina, North Dakota, Pennsylvania, Ohio, South Carolina, Texas, Virginia, West Virginia, and Wyoming.

Market Reach

1. Adventist Healthcare

2. AmerisourceBergen Corporation

3. Anda, Inc.

4. Ascension Healthcare

5. Attain Med, Inc.

Learn more from here.

Our Licenses and Certifications

 FDA Certificate of Free Sale

 DEA Controlled Substance Export License

 MD State Controlled Dangerous Substances Export License

 MD State Board of Pharmacy Distributor Licenses

 Florida Certificate of Good Manufacturing Practices

 Florida Certificate of Free Sales

 UL Certificate of Cosmetic cGMP

 ISO 22716:2007 Certificate

Locations and Facilities

Pacific United’s headquarters is located in Gaithersburg, MD, just five minutes from the I-270 Technology Corridor and 30 minutes from Washington D.C.

In 2018, Pacific United opened its own manufacturing facility in Tampa, FL with a capacity of 32,000 bottles per month. The facility is approved under Food and Drug Administration (FDA) guidelines and standards, with Good Manufacturing Practice (cGMP), UL and International Organization for Standardization (ISO) 22716 certificates.

Learn more from here.

Share this post

FarmaKology Newsletter - Issue #32

www.farmakology.com
Comments
TopNew

No posts

Ready for more?

© 2023 FarmaKology
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing